Riskpilot← Back to searchSign inGet full accessGENO R&D AS
ASActiveOrg 993130532Storhamargata 44, 2317 HamarResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20080 employees
Revenue 2024
NOK 18,9M
+27% vs 2023
EBITDA margin
-0.3%
+59% vs 2023
Equity ratio
11.0%
Financial strength
Net profit 2024
NOK 164K
+1037% vs 2023
| Revenue | NOK 18,9M | +27% |
| EBITDA | NOK -57K | +59% |
| Net profit | NOK 164K | +1037% |
| Total assets | NOK 16M | +50% |
| Equity | NOK 1,8M | +10% |
| Employees | 0 | — |
Legal name
GENO R&D AS
Org number
993130532
Legal form
Aksjeselskap
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
2. oktober 2008
Share capital
NOK 900 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets leder og ett styremedlem i fellesskap.
Company purpose
Drive forsknings og utviklingsarbeid, samt alt som naturlig står i forbindelse med dette.
Address
Storhamargata 44, 2317 Hamar
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1 473 | 4 810 | 4 094 | 4 287 | 714 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7 280 | 3 100 | 14 917 | 18 885 |
| Staff expenses | −916 | −4 208 | −3 841 | −3 950 | −688 | 5 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| EBITDA | −161 | −1 101 | −1 296 | −978 | −210 | −11 | −9 | −9 | −6 | −3 | −17 | −17 | −18 | −22 | −139 | −57 |
| Depreciation & amort. | −0 | −18 | −95 | −108 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| EBIT | −161 | −1 118 | −1 391 | −1 086 | −210 | −11 | −9 | −9 | −6 | −3 | −17 | −17 | −18 | −22 | −139 | −57 |
| Net financials | 126 | −972 | 291 | 4 923 | 81 | 18 | 33 | 54 | 53 | 62 | 68 | 55 | 1 | 36 | 122 | 221 |
| Profit before tax | −36 | −2 090 | −1 100 | 3 837 | −129 | 7 | 25 | 46 | 47 | 58 | 51 | 37 | −17 | 14 | −18 | 164 |
| Tax | −18 | −165 | −307 | −253 | −8 | 2 | 62 | 38 | 38 | 39 | 11 | 8 | 552 | −0 | −0 | −0 |
| Net profit | −18 | −1 925 | −794 | 4 089 | −121 | 5 | −37 | 7 | 9 | 19 | 40 | 29 | −569 | 14 | −18 | 164 |
| Item | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 17 980 | 19 656 | 20 907 | 25 292 | 2 195 | 2 107 | 2 070 | 2 077 | 2 086 | 2 105 | 2 145 | 2 174 | 12 843 | 2 720 | 10 720 | 16 035 |
| Equity | 16 952 | 15 027 | 14 233 | 18 322 | 2 101 | 2 107 | 2 070 | 2 077 | 2 086 | 2 105 | 2 145 | 2 174 | 1 605 | 1 619 | 1 602 | 1 766 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 1 029 | 1 130 | 674 | 970 | 93 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 11 238 | 1 100 | 9 119 | 14 268 |
| Total debt | 1 029 | 4 630 | 6 674 | 6 970 | 93 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 11 238 | 1 100 | 9 119 | 14 268 |
EBITDA margin
-0.3%
This company
15.8%
Market median
-102% vs market
20092024
Equity ratio
11.0%
This company
38.2%
Market median
-71% vs market
20092024
Return on equity
9.3%
This company
18.4%
Market median
-49% vs market
20092024
Net profit margin
0.9%
This company
8.1%
Market median
-89% vs market
20092024
Asset turnover
1.18×
This company
1.12×
Market median
+5% vs market
20092024
Debt / equity
8.08×
This company
0.62×
Market median
-1203% vs market
20092024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Brønnøysundsregistrene · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Brønnøysundsregistrene · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Brønnøysundsregistrene · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via Brønnøysundsregistrene · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via Brønnøysundsregistrene · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via Brønnøysundsregistrene · Period 2012-01-01 – 2012-12-31
- Annual report 2011Filed via Brønnøysundsregistrene · Period 2011-01-01 – 2011-12-31
- Annual report 2010Filed via Brønnøysundsregistrene · Period 2010-01-01 – 2010-12-31
- Annual report 2009Filed via Brønnøysundsregistrene · Period 2009-01-01 – 2009-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
HM Chief Executive Officer | Chief Executive Officer | 2021 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2021 | — | — | |
| Chairman | 2021 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Geno Sa | Company | 100.0% | 100.0% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Geno Sa
GENO R&D AS Board members of GENO R&D AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Håvard Melbø Tajet | Chief Executive Officer | 0 companies |
| Lars Skramstad | Board of Directors | 0 companies |
| Kristin Malonæs | Chairman | 0 companies |